Skip to content
Gold Mining News – Lifestyle
Author:
Vascarta Inc
Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins
August 19, 2026
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
June 24, 2026
Vascarta Announces Addition of Richard Serbin to Leadership Team
June 9, 2026